Trial Profile
Multicenter Phase II Trial Evaluating Pembrolizumab for the Treatment of Classical or Endemic Kaposi Disease [Essai de Phase II Multicentrique évaluant le Pembrolizumab Dans le Traitement de la Maladie de Kaposi Classique ou endémique]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Kaposi's sarcoma
- Focus Proof of concept; Therapeutic Use
- Acronyms KAPKEY
- 10 Mar 2022 Primary endpoint has been met (Best Overall Response Rate ), as per as per Results published in the Lancet Oncology
- 10 Mar 2022 Status has been changed to completed, as per Results published in the Lancet Oncology
- 10 Mar 2022 Final Results published in the Lancet Oncology